Provided by Tiger Trade Technology Pte. Ltd.

Monopar Therapeutics

55.46
-3.7800-6.38%
Post-market: 55.460.00000.00%16:10 EST
Volume:181.19K
Turnover:10.68M
Market Cap:370.62M
PE:-18.55
High:60.85
Open:59.05
Low:55.14
Close:59.24
52wk High:105.00
52wk Low:26.06
Shares:6.68M
Float Shares:4.93M
Volume Ratio:0.57
T/O Rate:3.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9895
EPS(LYR):-4.1123
ROE:-26.54%
ROA:-17.99%
PB:2.62
PE(LYR):-13.49

Loading ...

Monopar Therapeutics Price Target Maintained With a $104.00/Share by BTIG

Dow Jones
·
Feb 02

Monopar Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jan 29

Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Dyne Therapeutics (DYN)

TIPRANKS
·
Jan 21

BTIG Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Jan 14

Monopar Therapeutics Price Target Maintained With a $104.00/Share by BTIG

Dow Jones
·
Jan 14

Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Nuvalent (NUVL) and Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Jan 14

Monopar Therapeutics Initiated at Overweight by Morgan Stanley

Dow Jones
·
Jan 09

Morgan Stanley Initiates Coverage on Monopar Therapeutics With Overweight Rating, $115 Price Target

MT Newswires Live
·
Jan 09

Monopar Therapeutics: ALXN1840’s Differentiated Efficacy, De‑Risked Profile, and Strong Cash Runway Underpin Overweight/Buy Rating

TIPRANKS
·
Jan 09

JonesTrading Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Jan 09

The Year-End 2025 Biotech Rally And What It Means For 2026

Benzinga_recent_news
·
Dec 31, 2025

Monopar Therapeutics CFO Quan Anh Vu Acquires Common Shares

Reuters
·
Dec 30, 2025

Independent Director Arthur Klausner Sold A Bunch Of Shares In Monopar Therapeutics

Simply Wall St.
·
Dec 21, 2025

Stock Track | Monopar Therapeutics Soars 8.74% on Bullish Analyst Rating and $130 Price Target

Stock Track
·
Nov 19, 2025

Stock Track | Monopar Therapeutics Soars 8.74% Following Analyst's Buy Rating and $130 Price Target

Stock Track
·
Nov 19, 2025

Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position

TIPRANKS
·
Nov 19, 2025

Monopar Therapeutics Shares Fall After Raymond James Downgrade

MT Newswires Live
·
Nov 15, 2025

Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade

Stock Track
·
Nov 14, 2025

BTIG Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Nov 14, 2025

Monopar Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 14, 2025